Lenacapavir for HIV Prevention: A Commitment to Equitable Access and Partnership by Gilead Sciences

Jared M Baeten1

  • 1Gilead Sciences, Foster City, California, USA.

Summary

Lenacapavir is a novel HIV capsid inhibitor being developed for pre-exposure prophylaxis (PrEP). Gilead Sciences is planning equitable access strategies for global distribution to help end the HIV epidemic.